Added evidence for emicizumab in children with hemophilia A

18 April 2017

Swiss pharma major Roche (SIX: ROG) has announced interim results from the Phase III HAVEN 2 study evaluating emicizumab prophylaxis in children of less than 12 years of age with hemophilia A and inhibitors to factor VIII.

At this interim analysis after a median of 12 weeks of treatment, emicizumab prophylaxis showed a clinically-meaningful reduction in the number of bleeds over time, results which are consistent with findings from the Phase III HAVEN 1 study in adults and adolescents with hemophilia A and inhibitors to factor VIII.

In the earlier study the treatment also showed a statistically-significant and clinically-meaningful reduction in the number of bleeds over time compared to no prophylaxis, as well as compared to prior prophylaxis with bypassing agents.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK